Aeterna Zentaris (AEZS) Tops Q2 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/4/2026
- Dow claims record closing high, S&P 500 advances; chip selloff weighs on Nasdaq
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- HSBC stays aggressive on stocks, asks what could turn it bearish
- SpaceX sets IPO price at $135 ahead of roadshow in break with Wall Street norms
- Crypto stocks sink as Bitcoin hits a 4-month low
- Morgan Stanley lifts MU and SNDK targets, sees 2-3 years of tight memory supply
- Navitas showcases 800V power delivery board at NVIDIA MGX ecosystem event
- Inotiv files for bankruptcy with $65 million financing commitment
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Wells Fargo Upgrades Oscar Health Inc (OSCR) to Equal Weight 'on Greater Confidence in Exchange Market Trajectory in 2026'
Aeterna Zentaris Reports Second Quarter 2016 Financial and Operating Results
August 9, 2016 4:30 PM EDTNear-Term Major Inflection Point Approaching with Expected Completion of two Pivotal Phase 3 Programs in 2016
All $ amounts are in US Dollars
Key developments
Product development programs on track towards FDA submission in 2017 Zoptrex (zoptarelin doxorubicin) pivotal Phase 3 clinical program remains on track for completion in 2016 Macrilen (macimorelin) confirmatory Phase 3 Trial for the evaluation of AGHD also remains on track for completion in 2016 Zoptrex out-licensing activity successfully continues Zoptrex licensee in China and related territories, Sinopharm A-Think... More